Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and Malignant Mesothelioma

quinazolines has been researched along with Malignant Mesothelioma in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (87.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Berger, W; Brankovic, J; Cufer, T; Dome, B; Grasl-Kraupp, B; Grusch, M; Gschwandtner, E; Hegedus, B; Hoda, MA; Kern, I; Klepetko, W; Klikovits, T; Laszlo, V; Mohorcic, K; Peter-Vörösmarty, B; Pirker, C; Rozman, A; Schelch, K; Sinn, K; Vlacic, G1
Agostini, S; Barbarino, M; Barone, E; Bottaro, M; Catalano, C; Cipollini, M; Corrado, A; Dell'Anno, I; Gemignani, F; Giordano, A; Landi, S; Luzzi, L; Melaiu, O; Melani, A; Migliore, L; Silvestri, R1
Gandara, DR; Kalemkerian, GP; Kelly, K; Moon, J; Redman, MW; Tsao, AS; Vogelzang, NJ; Wistuba, II1
Cherubini, C; Drudi, F; Fantini, M; Lazzari-Agli, L; Papi, M; Sartori, S; Tamburini, E; Tassinari, D1
Heymach, J; Nakano, T; Nowak, AK; Popat, S; Scagliotti, GV; Tsao, A1
Box-Noriega, B; Fossella, FV; Gadgeel, S; Gandara, DR; Heymach, JV; Hueftle, JG; Kelly, K; Lu, C; Miao, J; Redman, MW; Tsao, AS; Velasco, MR; Vogelzang, NJ; Wistuba, II1
Nguyen, DM; Xin, HW; Yang, JH1
Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T1

Reviews

2 review(s) available for quinazolines and Malignant Mesothelioma

ArticleYear
Antimetabolites in the treatment of advanced pleural mesothelioma: a network meta-analysis of randomized clinical trials.
    Journal of chemotherapy (Florence, Italy), 2017, Volume: 29, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Network Meta-Analysis; Pemetrexed; Pleural Neoplasms; Quinazolines; Thiophenes; Treatment Outcome

2017
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Seminars in oncology, 2019, Volume: 46, Issue:2

    Topics: Asbestos; Bevacizumab; Carcinogenesis; Humans; Indoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neovascularization, Pathologic; Pleural Neoplasms; Quinazolines

2019

Trials

2 trial(s) available for quinazolines and Malignant Mesothelioma

ArticleYear
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Quinazolines

2017
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 10-01, Volume: 37, Issue:28

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Progression-Free Survival; Quinazolines

2019

Other Studies

4 other study(ies) available for quinazolines and Malignant Mesothelioma

ArticleYear
Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
    Cells, 2019, 09-16, Volume: 8, Issue:9

    Topics: Acrylamides; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Fibroblast Growth Factor, Type 4; Survival Analysis

2019
    International journal of molecular sciences, 2020, Jul-09, Volume: 21, Issue:14

    Topics: beta Karyopherins; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Epithelium; Eukaryotic Initiation Factor-4G; Gene Expression Regulation, Neoplastic; Humans; Mesothelioma, Malignant; Pleural Neoplasms; Quinazolines; ran GTP-Binding Protein; RNA, Small Interfering; Small Molecule Libraries

2020
Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma.
    Anticancer research, 2013, Volume: 33, Issue:6

    Topics: Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; ErbB Receptors; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Quinazolines; Signal Transduction

2013
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
    Oncology reports, 2015, Volume: 34, Issue:6

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2015